• GPC3-HSP70 mRNA Nanovaccine for HCC Immunotherapy

  2026-09-14

  The reference study develops a GPC3-targeted mRNA nanovaccine that combines tandem CTL epitopes, HSP70-mediated immune stimulation, and SP94-guided tumor delivery. In preclinical experiments, pairing the vaccine with anti-PD-L1 therapy strengthened antigen-specific T-cell responses and produced greater antitumor activity than either strategy alone.

• Clathrin-Mediated Entry of Type III GCRV

  2026-09-14

  Wang et al. used complementary inhibitor profiling, transmission electron microscopy, and quantitative PCR to define how genotype III grass carp reovirus enters CIK cells. Their results identify a dynamin-dependent, acidification-sensitive clathrin-mediated pathway and show that IPA-3 did not measurably block infection under the tested conditions, making it a useful negative pharmacological comparator rather than an antiviral lead in this study.

• Prochlorperazine: From Stroke Mimic to Assay Design

  2026-09-13

  Prochlorperazine is a dopamine D2 receptor antagonist with applications spanning antiemetic therapy, melanoma research, and mechanistic cell studies. This article develops a clinically informed framework for interpreting neurological phenotypes, selecting assay windows, and separating translational evidence from experimental hypothesis.

• Gly-Gly-Phe-Gly: A Linker for Assay Design

  2026-09-12

  Gly-Gly-Phe-Gly, or the GGFG peptide, can be treated as a controlled variable in bioconjugation assays rather than merely a passive spacer. This article connects linker chemistry with pharmacodynamic assay logic, biomarker interpretation, and practical handling decisions.

• Anti Reverse Cap Analog: mRNA Design Framework

  2026-09-11

  Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, improves the interpretability of synthetic mRNA experiments by favoring productive cap orientation. This guide connects cap chemistry with translation initiation, formulation decisions, and lessons from targeted mRNA delivery research.

• Bone Transport and TGF-β1 in Diabetic Foot Ulcers

  2026-09-11

  A 2026 rat study identifies TGF-β1/TGFBR1 signaling as a mechanistic link between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. The work combines proteomics with molecular, serological, and histological validation, while showing that pathway inhibition weakens the healing benefit of bone transport.

• p21–ELP Delivery Suppresses Glioblastoma Growth

  2026-09-10

  Quinn, Shaheen, and Raucher show that an elastin-like polypeptide and cell-penetrating peptide can deliver a p21-derived inhibitor into U87, GBM43, and GBM6 glioblastoma cells. The construct was internalized across all three models and primarily reduced proliferation through cytostatic effects, while apoptosis remained limited and varied by cell line.

• CX-5461 in Cervical Cancer: DNA Damage & Mitotic Catastrophe

  2026-09-10

  The June 2026 reference study identifies CX-5461 as an RNA polymerase I inhibitor that suppresses cervical cancer cell growth through DNA damage, dysregulated mitotic entry, and mitotic catastrophe. Its findings also support combining Pol I inhibition with cisplatin, while highlighting the need for model-specific validation before translating the approach to resistant or recurrent disease.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-09-09

  This 1992 study showed that several imidazoline α2-adrenoceptor antagonists stimulate insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than solely by blocking adrenergic receptors. Its paired pharmacological tests, 86Rb-efflux measurements, and patch-clamp experiments provide a useful framework for separating receptor-mediated effects from direct ion-channel modulation.

• Toremifene Versus Tamoxifen in Advanced Breast Cancer

  2026-09-09

  The Cochrane review directly compared toremifene with tamoxifen across randomized trials in advanced breast cancer and found no statistically significant differences in tumor response, time to progression, overall survival, or several reported adverse events. Its main contribution is a clinically focused synthesis that supports broadly similar efficacy and safety while cautioning researchers against interpreting a nonsignificant difference as proof of complete interchangeability.

• MALAT1–miR-135b-5p–GPNMB Axis in Parkinson’s Cells

  2026-09-08

  Lv et al. identified a MALAT1–miR-135b-5p–GPNMB regulatory axis that influences proliferation and apoptosis in MPP+-stimulated Parkinson’s disease cell models. The study combines loss-of-function experiments with molecular target validation, while its cell-based design also highlights the limits of translating neuroblastoma-model findings to human disease.

• Azilsartan medoxomil monopotassium: Assay Guide

  2026-09-08

  A scenario-based guide to using Azilsartan medoxomil monopotassium (SKU B1071) in cell viability, proliferation, and cytotoxicity workflows. It covers solubility, dose selection, controls, receptor-affinity interpretation, and practical product-selection criteria for hypertension and cardiovascular disease research.

• EDC.HCl: Practical Coupling Workflow

  2026-09-07

  EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation with primary amines in controlled laboratory workflows. This guide covers handling, setup, monitoring, and troubleshooting for peptide, bioconjugation, nucleotide, esterification, and related in vitro applications; the supplied dossier provides no in vivo or clinical evidence.

• Recombinant Mouse SHH in Translational Patterning

  2026-09-07

  A mechanistic and strategic guide to using Recombinant Mouse Sonic Hedgehog as a controlled perturbation tool for developmental biology, comparative morphogenesis, and congenital malformation research.

• Dacomitinib: Pan-HER Workflows for Cancer Research

  2026-09-05

  Dacomitinib (PF-00299804) combines irreversible ErbB-family inhibition with experimentally useful effects on receptor signaling, cell-cycle progression, and apoptosis. This guide shows how to deploy it in NSCLC, HER2-amplified breast cancer, and exploratory mitochondrial ferroptosis workflows without overstating evidence across disease models.

8067 records 1/538 page Next 12345 下5页 Last page